A Risk Score Model for Locoregional Recurrence Following Upfront Surgery for Pancreatic Adenocarcinoma: Implications for Adjuvant Therapy
| Autor: | Hamzeh Albaba, Shawn Hutchinson, J. Kim, Steve Gallinger, Aisling Barry, S. Kalimuthu, Anna Dodd, Rebecca M. Prince, Sareh Keshavarzi, Raimond Wong, I. McGilvary, Sean P. Cleary, A.M. Elamir, C.-A. Moulton, Laura A. Dawson, W. Xu, Grainne M. O'Kane, Ali Hosni, Jolie Ringash, Alice Chia-chi Wei, Jennifer J. Knox, J.D. Brierley |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Lymphovascular invasion Adenocarcinoma 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Port (medical) Risk Factors medicine Adjuvant therapy Humans Radiology Nuclear Medicine and imaging Retrospective Studies Framingham Risk Score business.industry Postoperative radiation medicine.disease Confidence interval Surgery Pancreatic Neoplasms Oncology 030220 oncology & carcinogenesis Cohort Radiotherapy Adjuvant Neoplasm Recurrence Local business |
| Zdroj: | Clinical Oncology. 33:527-535 |
| ISSN: | 0936-6555 |
| DOI: | 10.1016/j.clon.2021.03.007 |
| Popis: | Aims The aims of the study were to identify predictors of locoregional failure (LRF) following surgery for pancreatic adenocarcinoma, develop a prediction risk score model of LRF and evaluate the impact of postoperative radiation therapy (PORT) on LRF. Materials and methods A retrospective review was conducted on patients with stages I–III pancreatic adenocarcinoma who underwent surgery at our institution (2005–2016). Univariable and then multivariable analyses were used to evaluate clinicopathological factors associated with LRF for patients who did not receive PORT. The risk score of LRF was calculated based on the sum of coefficients of the predictors of LRF. The model was applied to the entire cohort to evaluate the impact of PORT on the high- and low-risk groups for LRF. Results In total, 467 patients were identified (median follow-up 22 months). Among patients who did not receive PORT (n = 440), predictors of LRF were pN+, involved or close ≤1 mm margin(s), moderately and poorly differentiated tumour grade and lymphovascular invasion. After adding patients who received PORT, the 2-year LRF in the high-risk group was 57% for patients who did not receive PORT (n = 242) and 32% among patients who received PORT (n = 22), with an absolute benefit to LRF of 25% (95% confidence interval 5–52%, P = 0.07). The 2-year overall survival for the high-versus the low-risk group was 36% versus 67% (P Conclusion This risk group classification could be used to identify pancreatic adenocarcinoma patients with higher risk of LRF who may benefit from PORT. However, validation and prospective evaluation are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect